摘要
目的 探究红景天注射液对帕金森病患者治疗效果及血清DJ-1/核因子相关因子2(Nrf2)通路相关氧化应激指标的影响。方法 前瞻性选取2021年6月至2022年6月来河北北方学院附属第一医院治疗的120例帕金森病患者作为研究对象,按照随机数字表法将患者分为研究组与对照组,每组各60例。对照组患者接受常规抗帕金森病治疗,研究组患者在此基础上联用红景天注射液治疗,连续治疗4周。比较两组患者的临床疗效,治疗前、治疗后4周的氧化应激指标[超氧化物歧化酶(SOD)、丙二醛、谷胱苷肽过氧化物酶(GSH-Px)、DJ-1蛋白、Nrf2],治疗前、治疗后4个月的帕金森病综合症状、生活质量情况,并观察两组患者不良反应发生情况。结果 治疗后,观察组患者的治疗有效率为96.61%,明显高于对照组(83.05%),差异有统计学意义(P<0.05)。治疗后4周,观察组患者血清SOD、GSH-Px、Nrf2水平分别为(44.27±2.19) U/mL、(44.12±6.72) U/L、(669.68±87.23) U/L,均明显高于对照组[(31.29±2.97) U/mL、(40.82±4.12) U/L、(602.09±52.31) U/L],而血清丙二醛、DJ-1蛋白水平分别为(2.27±0.86) nmol/mL、(7.08±2.19)μg/L,均明显低于对照组(3.69±1.15) nmol/mL、(10.92±1.29)μg/L,差异均有统计学意义(P<0.05)。治疗后4个月,观察组患者的UPDRS评分为(46.23±2.34)分,明显低于对照组[(63.28±1.93)分],差异有统计学意义(P<0.05)。治疗后4个月,观察组患者的生理功能、躯体功能、社会功能、心理状态、情感功能5个方面的评分分别为(73.12±5.22)、(78.23±2.34)、(81.23±2.13)、(88.29±3.91)、(86.39±3.23)分,均明显高于对照组[(53.13±6.48)、(59.28±4.92)、(69.24±5.91)、(71.23±2.03)、(71.13±3.25)分],差异均有统计学意义(P<0.05)。治疗后,观察组患者不良反应发生率为8.47%,明显低于对照组(23.73%),差异有统计学意义(P<0.05)。结论 在常规抗帕金森病治疗基础上,采用红景天注射液治疗帕金森病可明显提高患者的临床疗效,抑制DJ-1/Nrf2通路相关氧化应激反应,改善帕金森病症状,提高患者生活质量,降低不良反应发生率。
Objective To explore the effect of Rhodiola injection on the treatment efficacy and the oxidative stress indicators related to serum DJ-1/nuclear factor related factor 2(Nrf-2) pathway in the patients with Parkinson's disease.Methods A total of 120 patients with Parkinson's disease from Hebei North University Affiliated First Hospital from June 2021 to June 2022 were prospectively selected as the study subjects,and divided into the study group and the control group according to the random number table method,with 60 cases in each group.The control group was treated with conventional anti Parkinson's disease treatment,and the study group was treated with Rhodiola injection,continuous treatment for 4 weeks.The clinical efficacy of two groups of patients was compared.The oxidative stress index[superoxide dismutase(SOD),malondialdehyde,glutathione peroxidase(GSH-Px),DJ-1 protein,Nrf2] of two groups of patients were compared before treatment and after 4 weeks of treatment,and comprehensive symptoms of Parkinson's disease,quality of life were compared before treatment and after 4 months of treatment,occurrence of adverse reactions were compared.Results After treatment,the treatment response rate of patients in the observation group was 96.61%,which was significantly higher than that in the control group(83.05%),the difference was statistically significant(P<0.05).After 4 weeks of treatment,the levels of serum SOD,GSH-Px,and Nrf2 in the observation group were(44.27±2.19) U/mL,(44.12±6.72) U/L,and(669.68±87.23) U/L,respectively,which were significantly higher than those in the control group [(31.29±2.97) U/mL,(40.82±4.12) U/L,(602.09±52.31) U/L],while the levels of serum malondialdehyde and DJ-1 protein were(2.27±0.86) nmol/mL,(7.08±2.19) μg/L,respectively,which were significantly lower than those in the control group [(3.69±1.15) nmol/mL,(10.92±1.29) μg/L],the differences were statistically significant(P<0.05).After 4 weeks of treatment,the UPDRS score in the observation group was(46.23±2.34) points,which was significantly lower than that in the control group [(63.28±1.93) points],the difference was statistically significant(P<0.05).After 4 months of treatment,the scores of physiological function,physical function,social function,psychological state,and emotional function in the observation group were(73.12±5.22),(78.23±2.34),(81.23±2.13),(88.29±3.91),and(86.39±3.23) points,respectively,which were significantly higher than those in the control group [(53.13±6.48),(59.28±4.92),(69.24±5.91),(71.23±2.03),and(71.13±3.25) points],the differences were statistically significant(P<0.05).After treatment,the incidence of adverse reactions in the observation group was 8.47%,which was significantly lower than that in the control group(23.73%),the difference was statistically significant(P<0.05).Conclusion On the basis of conventional anti Parkinson's disease treatment,the application of Rhodiola injection in the treatment of Parkinson's disease can significantly improve the clinical efficacy of patients,inhibit DJ-1/Nrf-2 pathway related oxidative stress response,improve Parkinson's disease symptoms,improve the quality of life of patients,reduce the incidence of adverse reactions.
作者
谷伟
孙梓旭
贾海莉
杨继雷
孙光宁
GU Wei;SUN Zi-xu;JIA Hai-li(Hebei North University Affiliated First Hospital,Zhangjiakou Hebei 075000,China)
出处
《临床和实验医学杂志》
2024年第3期254-258,共5页
Journal of Clinical and Experimental Medicine
基金
河北省卫生健康委科研课题(编号:20220622,20231460)。
